Nintedanib has received an expanded indication to include interstitial lung disease (ILD) that’s associated with scleroderma—a rare autoimmune disorder that causes abnormal connective tissue growth throughout the body. Nintedanib is the first therapy approved for adults with this rare lung condition. It was approved in 2014 to treat idiopathic pulmonary fibrosis, another interstitial lung disease.
Sancar F. First Treatment for Lung Disease Related to Scleroderma. JAMA. 2019;322(15):1442. doi:10.1001/jama.2019.16349
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: